Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-371
Closed -$116K 120
2025
Q1
$116K Hold
371
0.02% 122
2024
Q4
$96.7K Sell
371
-16
-4% -$4.75K 0.02% 117
2024
Q3
$125K Hold
387
0.02% 111
2024
Q2
$121K Hold
387
0.02% 113
2024
Q1
$110K Hold
387
0.02% 114
2023
Q4
$111K Sell
387
-23
-6% -$6.27K 0.02% 99
2023
Q3
$110K Sell
410
-1,082
-73% -$270K 0.02% 102
2023
Q2
$331K Sell
1,492
-1,851
-55% -$430K 0.06% 105
2023
Q1
$808K Sell
3,343
-77
-2% -$18.9K 0.12% 92
2022
Q4
$898K Buy
3,420
+389
+13% +$104K 0.14% 95
2022
Q3
$683K Sell
3,031
-620
-17% -$150K 0.11% 102
2022
Q2
$888K Buy
3,651
+1,275
+54% +$312K 0.13% 97
2022
Q1
$574K Sell
2,376
-3
-0.1% -$689 0.08% 115
2021
Q4
$535K Buy
2,379
+405
+21% +$85.5K 0.06% 117
2021
Q3
$419K Buy
1,974
+175
+10% +$40.3K 0.05% 119
2021
Q2
$438K Hold
1,799
0.05% 116
2021
Q1
$447K Buy
1,799
+291
+19% +$69.4K 0.05% 109
2020
Q4
$346K Buy
1,508
+1,023
+211% +$236K 0.04% 101
2020
Q3
$123K Sell
485
-463
-49% -$115K 0.02% 83
2020
Q2
$224K Sell
948
-23
-2% -$5.25K 0.05% 56
2020
Q1
$197K Sell
971
-467
-32% -$102K 0.07% 54
2019
Q4
$347K Buy
1,438
+433
+43% +$95.4K 0.12% 57
2019
Q3
$194K Buy
1,005
+90
+10% +$17.3K 0.02% 69
2019
Q2
$169K Hold
915
0.01% 72
2019
Q1
$174K Buy
915
+272
+42% +$51.9K 0.09% 49
2018
Q4
$125K Buy
+643
New +$125K 0.06% 55

Other funds holding AMGN

Mirova's AMGN Position: Q2 2025 in Review

Mirova sold out of Amgen (AMGN) in Q2 2025, closing a stake of 371 shares — an estimated $116K sold.

Mirova first reported a position in AMGN in Q4 2018 and held it in 26 quarters. The position peaked at $898K in Q4 2022. 2,851 funds tracked by Wall St. Rank hold AMGN as of Q2 2025.

  • Mirova reported no remaining Amgen position as of Q2 2025 after selling out during the quarter.
  • Mirova sold 371 Amgen shares in Q2 2025, an estimated $116K.
  • Mirova first reported a position in Amgen in Q4 2018 and held it in 26 quarters.
  • Mirova's Amgen position peaked at $898K in Q4 2022.
  • 2,851 funds tracked by Wall St. Rank held Amgen as of Q2 2025.

Based on Mirova's 13F filing for Q2 2025, filed 13 Aug 2025.